· Use of topical ointments instead of creams or gels

· Avoidance of trigger factors (mechanical factors such as trauma, unnecessary surgical interventions, piercings) and irritants (excessive water exposure or cleansing products, synthetic and tight clothing, use of wet wipes, etc.)

· Avoidance of over-the-counter medications, lenitive herbal products, topical antihistamines and anesthetics and perfumed products is suggested

· Co-treatment with topical emollients is recommended during standard therapy in women with genital LS.

· Co-treatment with topical emollients is recommended for girls with genital LS.

· Co-treatment with topical emollients is suggested for men and boys with genital LS.

· Co-treatment with topical emollients is suggested for patients with extragenital LS.

· Ultrapotent or potent topical corticosteroids are recommended for women, girls, men, and boys with genital LS.

· Ultrapotent or potent topical corticosteroids are suggested for patients with extragenital LS.

· Topical steroid ointments are recommended instead of creams and lotions.

· Intralesional corticosteroids to hyperkeratotic lesions are suggested for women with topical steroid-resistant genital LS, if malignancy has been excluded.

· UVA 1 therapy is suggested in women with genital LS as a second-choice treatment, taking into account carcinogenicity and practicality.

· A recommendation against UV therapy was made for girls with genital LS.

· A recommendation could not be made with respect to UV therapy in men with genital LS.

· A recommendation against UV therapy was made for boys with genital LS.

· UV therapy is recommended in patients with extragenital LS.

· A recommendation for the use of photodynamic therapy for adults with genital LS could not be made.

· A recommendation against photodynamic therapy was made for children with LS.

· A recommendation for the use of photodynamic therapy for patients with extragenital LS could not be made (off-label).

· A recommendation for the use of laser therapy in adults could not be made.

· A recommendation against laser therapy was made for children with LS.

· Acitretin is suggested for women with genital LS, if systemic therapy is needed, taking into account teratogenicity (off-label).

· Acitretin is suggested for men with genital LS, if systemic therapy is needed (off-label).

· Methotrexate is suggested for adults with genital and/or extragenital LS, taking into account teratogenicity, if systemic therapy is needed (off-label).

· A recommendation against potassium para-aminobenzoate as systemic therapy was made.

· Adhesion/de-adhesion/synechiolysis/perineoplasty is suggested for women with LS who have persistent introital stenosis that causes mechanical problems in voiding or sexual intercourse, despite guideline-conform treatment with steroids.· A recommendation against surgical treatment was made for the management of genital LS in girls.

· Circumcision is suggested, preferably removing the complete foreskin if guideline-conform treatment with e.g., steroids in men with phimosis caused by LS fails.

· Frenuloplasty is suggested in combination with intralesional triamcinolone or, alternatively, a complete circumcision if guideline-conform treatment with e.g., steroids in men with scarring or shortening of the frenulum caused by LS fails.

· Urethroplasty is suggested using oral mucosa grafts in men with urethral stricture due to LS, causing mechanical problems in voiding or sexual intercourse.

· Circumcision is suggested, preferably removing the complete foreskin if guideline-conform treatment with e.g., steroids in boys with phimosis caused by LS fails.

· Frenuloplasty is suggested in combination with intralesional triamcinolone, or alternatively, a complete circumcision if guideline-conform treatment with e.g., steroids fails in boys with scarring or shortening of the frenulum caused by LS.